US Markets

Mallinckrodt to sell unit BioVectra for up to $250 mln

Drugmaker Mallinckrodt Plc said on Tuesday it would sell its unit BioVectra Inc to private equity firm H.I.G. Capital for up to $250 million.

Sept 10 (Reuters) - Drugmaker Mallinckrodt Plc MNK.N said on Tuesday it would sell its unit BioVectra Inc to private equity firm H.I.G. Capital for up to $250 million.

The news comes as opioid makers in the United States, including Mallinckrodt, face pressure from a crackdown on the addictive drug in the wake of a crisis and as state attorneys general file lawsuits against manufacturers.

Investors have worried about the company's large debt pile and potential payouts to resolve opioid litigation, but Mallinckrodt has downplayed concerns that it may choose to seek bankruptcy protection.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More